Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Operating as a biopharmaceutical firm in Poland, Molecure S.A. specializes in the research, development, and commercialization of innovative therapies designed to combat neoplastic (cancer) and inflammatory conditions. The company's pipeline prominently features OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has successfully advanced through Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and sarcoidosis. Additionally, Molecure is progressing its YKL-40 program for cancer and fibrosis, OATD-02 for oncology applications, and a Deubiquitinase program. Established in 2012, this Warsaw-headquartered enterprise adopted the name Molecure S.A. in March 2022, having previously been known as OncoArendi Therapeutics S.A.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.
Target Price
The average target price of MOC.WA is 13.6 and suggests 127% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc